ArticleEuropean child & adolescent psychiatry2025
Duration of ADHD medication treatment among Finnish children and adolescents ‒ a nationwide register study.
Article in European child & adolescent psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methylphenidate Treatment and Risk of Psychotic Disorder.JAMA psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo study the duration of attention-deficit/hyperactivity disorder (ADHD) medication treatment among children and adolescents by sex and age group in Finland during 2008-2019.
methodsThis was a descriptive, population-based register study covering all Finnish children and adolescents aged 6-18 years who initiated their first ADHD medication treatment period between January 1, 2008 and December 31, 2019 (n = 40691). To establish the duration of use we collected data from the register of Dispensations reimbursable under the National Health Insurance Scheme register. The median follow-up time was 3.8 years (Q1 = 1.7, Q3 = 7.1). Treatment duration was calculated as the interval between the date of the first and last purchase with a cut-off of 365 days allowed between purchases. The durations were estimated using Kaplan-Meier survival times.
resultsThe median duration of ADHD medication treatment was 3.2 years (95% CI 3.2, 3.3, Q1 = 1.0 95% CI 0.9, 1.0, Q3 = 6.8 95% CI 6.7, 7.0). Sex and age significantly influenced treatment duration (p <.0001 and p <.0001). Boys had longer treatment duration than girls and the younger the subject, the longer the duration of usage. Boys aged 6-8 years (32.4% of the subjects) exhibited the longest treatment duration with a median of 6.3 years (95% CI 6.2, 6.5, Q1 = 2.6 95% CI 2.5, 2.7, Q3 = 9.4 years 95% CI 9.2, 9.6).
conclusionsThe duration of ADHD medication treatment among children in the real-world clinical setting goes well beyond the data available from randomized controlled trials and extends for several years especially among young boys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.